不同剂量瑞舒伐他汀钙对急性冠脉综合征非介入药物保守治疗患者的影响研究

摘要

目的：探讨不同剂量瑞舒伐他汀钙(10 mg和20 mg)对急性冠脉综姓合征(ACS)非PCI药物保守治疗患者血清铁蛋白、血脂水平及炎性因子的影响。方法将2010年1月—2014年6月该院收治的ACS非PCI药物保守治疗患者120例随机分为A、B、C 3组各40例，在给予吸氧、抗凝、扩张冠脉血管等治疗的基础上，A组口服瑞舒伐他汀钙10 mg，B组口服瑞舒伐他汀钙20 mg，C组口服阿托伐他汀钙20 mg，均1次/d。治疗前和治疗16周后抽取静脉血，观察3组治疗前后血清LDL、oxLDL、hsCRP水平。结果 A组治疗后血清铁蛋白、LDL、oxLDL、hsCRP分别为(189.27±11.15) ng/mL、(3.08±0.17) mmol/L、(45.17±1.63) mmol/L、(5.48±0.22) mmol/L；B组治疗后血清铁蛋白、LDL、oxLDL、hsCRP分别为(89.24±12.16) ng/mL、(2.51±0.31) mmol/L、(40.78±0.69) mmol/L、(4.34±0.27) mmol/L；C组治疗后血清铁蛋白、LDL、oxLDL、hsCRP分别为(195.78±13.65)ng/mL、(3.11±0.21) mmol/L、(45.24±1.71) mmol/L、(5.49±0.27) mmol/L。三组患者治疗16周后血清铁蛋白、血清LDL、oxLDL、hsCRP水平均较治疗前明显降低(P<0．05)。其中B组较A、C组降低明显(P<0．05)，A组与C组比较有差异，但差异无统计学意义(P＞0．05)。结论 ACS非PCI药物保守治疗患者早期使用不同剂量瑞舒伐他汀钙能明显降低血清LDL、oxLDL、hsCRP水平，降低血脂水平，降低炎性因子，减轻炎性反应，可能起到稳定斑块、抗栓、改善预后的作用。%Objective To investigate the effects of different dose of rosuvastatin (10 mg and 20 mg) in patients with acute coronary syndrome (ACS) affects non PCI drug conservative treatment in patients with serum ferritin, serum lipid level and inflammatory factors. Methods 120 cases of ACS were randomly divided into A, B, C three groups of 40 cases, based on given oxygen, anticoagulation, dilating coronary artery and other treatment, group A received oral administration of rosuvastatin 10mg, group B received oral administration of rosuvastatin 20 mg, C group received atorvastatin calcium 20mg, all 1/d. 16 weeks before and after the treatment of venous blood, three groups were observed before and after treatment the serum LDL, oxLDL, hsCRP level. Results A group after treatment, serum ferritin, LDL, oxLDL, hsCRP were (189.27±11.15), (3.08±0.17) ng/ml mmol/L, (45.17±1.63), (5.48± 0.22) mmol/L mmol/L;B group after treatment, serum ferritin, LDL, oxLDL, hsCRP were (89.24±12.16) ng/ml, (2.51±0.31) mmol/L, (40.78±0.69) mmol/L (4.34±0.27), mmol/L;C group after treatment, serum ferritin, LDL, oxLDL, hsCRP were (195.78±13.65)ng/mL, (3.11±0.21), (45.24±1.71,5.49) mmol/L (5.49+0.27) mmol/L. three patients in treatment group were significantly lower than that before treatment after 16 weeks, serum ferritin, serum LDL, oxLDL, hsCRP levels (P < 0.05). The B group than in A group, C decreased significantly (P < 0.05), A group and C group with a difference, but no statistical significance (P > 0.05). Conclusion ACS non PCI drug conservative treatment in patients with different doses of Rui Shu early atorvastatin can decrease serum LDL, oxLDL, hsCRP levels, reduce blood lipid levels, reduce inflammatory factors, inflammatory reaction, could play a stable plaque, anti thrombus, improve the prognosis role.